Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT00174434 Completed - Breast Neoplasms Clinical Trials

Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

Start date: September 2005
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

NCT ID: NCT00174343 Completed - Breast Neoplasms Clinical Trials

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Start date: November 2001
Phase: Phase 2
Study type: Interventional

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

NCT ID: NCT00173303 Not yet recruiting - Breast Cancer Clinical Trials

The Diagnostic Efficacy of Computer-Aided Detection (CAD) in Full-Field Digital Mammography (FFDM)- A Prospective Study

Start date: January 2006
Phase: N/A
Study type: Observational

The purpose of this study is to evalute whether CAD (computer-aided detection) in FFDM (full-field digital mammography) can facilitate the detection rate of breast cancer on mammography compared with FFDM without CAD.

NCT ID: NCT00172068 Terminated - Clinical trials for Primary Breast Cancer

Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow

MRD-1
Start date: January 2002
Phase: Phase 2
Study type: Interventional

Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases. This open-label study will investigate the safety and efficacy of zoledronic acid in patients with breast cancer and minimal residual disease in the bone marrow.

NCT ID: NCT00172029 Completed - Clinical trials for Breast Cancer With Metastatic Bone Disease

Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid

Start date: April 2003
Phase: Phase 4
Study type: Interventional

The aim of this prospective, randomized, open-label, multicentric clinical study is to assess the effícacy and tolerability of zoledronic acid 4 mg IV infused over 15 minutes every 4 weeks for a total of 6 infusions, in combination with standard or reduced dose radiotherapy in patients with breast cancer and metastatic bone disease associated with pain.

NCT ID: NCT00171847 Terminated - Clinical trials for Metastatic Breast Cancer

Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer

eLEcTRA
Start date: March 2003
Phase: Phase 4
Study type: Interventional

Phase IV trial to investigate the effect of the combination of Letrozole with trastuzumab in metastatic breast cancer patients

NCT ID: NCT00171704 Completed - Clinical trials for Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer

Start date: April 2005
Phase: Phase 3
Study type: Interventional

Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis. This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.

NCT ID: NCT00171340 Completed - Breast Cancer Clinical Trials

Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

Start date: May 2003
Phase: Phase 3
Study type: Interventional

Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.

NCT ID: NCT00171314 Completed - Breast Cancer Clinical Trials

The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer

Start date: March 2004
Phase: Phase 3
Study type: Interventional

Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.

NCT ID: NCT00170235 Completed - Breast Cancer Clinical Trials

Reducing Arm Morbidity in Pre- and Post-breast Cancer Surgery

Start date: August 2004
Phase: N/A
Study type: Interventional

The overall aim of this pilot study is to explore the feasibility of a randomized trial to test the effectiveness of physical therapy, provided both pre- and post-surgery, on reducing arm morbidity and increasing health-related quality of life (HRQL) post-surgery.